OBI Pharma (4174) reported revenue of NT$2.3 million for Oct 2026, -58.7% year on year and +40.8% from the previous month. Revenue for Jan–Oct 2026 was NT$29.6 million (-31.5% year on year).
In Oct 2026, it ranked No. 140 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$2.3 million | -58.7% | +40.8% |
| Sep 2026 | NT$1.6 million | -69.7% | +98.5% |
| Aug 2026 | NT$817,000 | -23.4% | -80.0% |
| Jul 2026 | NT$4.1 million | -0.6% | -60.4% |
| Jun 2026 | NT$10.3 million | +165.9% | +580.5% |
| May 2026 | NT$1.5 million | -59.5% | -56.0% |
| Apr 2026 | NT$3.4 million | -32.8% | +30.7% |
| Mar 2026 | NT$2.6 million | -9.8% | +65.6% |
| Feb 2026 | NT$1.6 million | -85.5% | +19.5% |
| Jan 2026 | NT$1.3 million | +140.2% | -81.9% |
| Dec 2025 | NT$7.4 million | -5.9% | -7.0% |
| Nov 2025 | NT$7.9 million | +306.2% | +43.7% |
| Oct 2025 | NT$5.5 million | +215.0% | +3.2% |
| Sep 2025 | NT$5.4 million | +14.8% | +401.4% |
| Aug 2025 | NT$1.1 million | -82.1% | -74.0% |
| Jul 2025 | NT$4.1 million | -66.8% | +5.8% |
| Jun 2025 | NT$3.9 million | -51.8% | +3.5% |
| May 2025 | NT$3.7 million | -43.9% | -27.0% |
| Apr 2025 | NT$5.1 million | +19.9% | +75.5% |
| Mar 2025 | NT$2.9 million | -9.4% | -73.4% |
| Feb 2025 | NT$11 million | +145.2% | +1,878.2% |
| Jan 2025 | NT$555,000 | -61.2% | -92.9% |
| Dec 2024 | NT$7.8 million | +10.2% | +301.5% |
| Nov 2024 | NT$2 million | -70.1% | +11.4% |
| Oct 2024 | NT$1.8 million | -63.2% | -62.4% |
Jan–Oct 2026 cumulative: NT$29.6 million (-31.5% YoY)
Other Biotech & Medical companies
Compare with peers: OBI Pharma vs PEC / OBI Pharma vs Lotus Pharm / OBI Pharma vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
潤雅子公司提供CDMO之服務收入於滿足履約義務時認列,本月及本年累計完成履約義務較去年減少
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16